Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin + Cetuximab in later-line metastatic RAS wild-type colorectal cancer
ChiCTR2600121010Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of becotatug vedotin and cetuximab in colorectal cancer (CRC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
becotatug vedotincetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2600121010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121010.